Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014

Hematology/Oncology Clinics of North America

Volumn 28, Issue 5, 2014, Pages 815-827

  Landau, Heather ^a,b   Giralt, Sergio ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Corticosteroids; Dexamethasone; Melphalan; Stem cell transplantation; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IXAZOMIB CITRATE; LENALIDOMIDE; PREDNISONE; THALIDOMIDE;

ALLOTRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; HIGH DOSE MELPHALAN THERAPY; HUMAN; INDUCTION CHEMOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHARMACEUTICAL CARE; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL RATE; SURVIVAL TIME; AUTOTRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PROCEDURES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEXAMETHASONE; HUMANS; INDUCTION CHEMOTHERAPY; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84912574090     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.06.004     Document Type: Review

References (70)

1. McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983, 2(8354):822-824.
2. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92(9):3131-3136.
3. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348(19):1875-1883.
4. Blade J., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106(12):3755-3759.
5. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. JClin Oncol 2005, 23(36):9227-9233.
6. Attal M., Harousseau J.L., Stoppa A.M., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. NEngl J Med 1996, 335(2):91-97.
7. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89(3):789-793.
8. Lenhoff S., Hjorth M., Holmberg E., et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000, 95(1):7-11.
9. Alexanian R., Weber D., Giralt S., et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001, 27(10):1037-1043.
10. Richardson P.G., Mitsiades C., Schlossman R., et al. New drugs for myeloma. Oncologist 2007, 12(6):664-689.
11. Randomized trial of lenalidomide, bortezomib and dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (DFCI 10-106) (IFM DFCI 2009). Available at:. Accessed July 17, 2014. http://clinicaltrials.gov/show/NCT01208662.
12. Study to compare VMP with HDM followed by VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (EMN 2) (H095). Available at:. Accessed July 17, 2014. http://clinicaltrials.gov/show/NCT01208766.
13. Alvares C.L., Davies F.E., Horton C., et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005, 129(5):607-614.
14. Lokhorst H.M., van der Holt B., Zweegman S., et al. Arandomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115(6):1113-1120.
15. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. JClin Oncol 2010, 28(30):4621-4629.
16. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376(9758):2075-2085.
17. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30(24):2946-2955.
18. Reeder C.B., Reece D.E., Kukreti V., et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010, 115(16):3416-3417.
19. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116(5):679-686.
20. Rajkumar S.V., Rosinol L., Hussein M., et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. JClin Oncol 2008, 26(13):2171-2177.
21. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11(1):29-37.
22. Kumar S., Flinn I., Richardson P.G., et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, 119(19):4375-4382.
23. Moreau P., Avet-Loiseau H., Facon T., et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011, 118(22):5752-5758. [quiz: 5982].
24. Reeder C.B., Reece D.E., Kukreti V., et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009, 23(7):1337-1341.
25. Lenalidomide and dexamethasone with or without bortezomib in treating patients with previously untreated multiple myeloma.
26. Hofmeister C.C., Rosenbaum C.A., Htut M., et al. Twice-weekly oral MLN9708 (Ixazomib Citrate), an investigational proteasome inhibitor, in combination with lenalidomide (Len) and dexamethasone (Dex) in patients (Pts) with newly diagnosed multiple myeloma (MM): final phase 1 results and phase 2 data. Blood 2013, 122(21):535.
27. Jakubowiak A.J., Dytfeld D., Griffith K.A., et al. Aphase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120(9):1801-1809.
28. Lahuerta J.J., Mateos M.V., Martinez-Lopez J., et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. JClin Oncol 2008, 26(35):5775-5782.
29. Salwender H., Rosiñol L., Moreau P., et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood 2013, 122(21):767.
30. Haessler J., Shaughnessy J.D., Zhan F., et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007, 13(23):7073-7079.
31. Hoering A., Crowley J., Shaughnessy J.D., et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009, 114(7):1299-1305.
32. Barlogie B., Anaissie E., Haessler J., et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008, 113(2):355-359.
33. Chng W.J., Dispenzieri A., Chim C.S., et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014, 28(2):269-277.
34. Palumbo A., Cavallo F., Hardan I., et al. Melphalan/Prednisone/Lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients <65 years: results of a randomized phase III study. Blood 2011, 118(21):3069.
35. Gay F., Spencer A., Di Raimondo F., et al. Aphase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood 2013, 122(21):763.
36. Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (DFCI 10-106). Available at:. Accessed July 17, 2014. http://clinicaltrials.gov/show/NCT01208662.
37. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. NEngl J Med 2003, 349(26):2495-2502.
38. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. JClin Oncol 2007, 25(17):2434-2441.
39. A trial of single autologous transplant with or without consolidation therapy versus tandem autologous transplant with lenalidomide maintenance for patients with multiplemyeloma (BMT CTN 0702). Available at:. Accessed July 17, 2014. http://clinicaltrials.gov/show/NCT01109004.
40. Siegel D.S., Jacobus S., Rajkumar S.V., et al. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 randomized clinical trial. Blood 2010, 116(21):38.
41. Kumar S.K., Lacy M.Q., Dispenzieri A., et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012, 118(6):1585-1592.
42. Lenalidomide and dexamethasone with/without stem cell transplant in patients with multiple myeloma. Available at:. Accessed July 17, 2014. http://clinicaltrials.gov/show/NCT01731886.
43. Lenalidomide (Revlimid) plus low-dose dexamethasone (ld × 4 cycles) then stem cell collection followed by randomization to continued Ld or stem cell transplantation (SCT) plus maintenance L. Available at:. Accessed July 17, 2014. http://clinicaltrials.gov/show/NCT00807599.
44. Kumar S., Giralt S., Stadtmauer E.A., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114(9):1729-1735.
45. Qazilbash M.H., Saliba R.M., Hosing C., et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007, 39(5):279-283.
46. O'Shea D., Giles C., Terpos E., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006, 37(8):731-737.
47. Kumar S.K., Dingli D., Lacy M.Q., et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 2008, 83(8):614-617.
48. El Cheikh J., Kfoury E., Calmels B., et al. Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. Hematol Oncol Stem Cell Ther 2011, 4(1):30-36.
49. Bashir Q., Shah N., Parmar S., et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged>/=70 years with multiple myeloma. Leuk Lymphoma 2012, 53(1):118-122.
50. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. JClin Oncol 2010, 28(12):2077-2084.
51. Cavo M., Pantani L., Petrucci M.T., et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120(1):9-19.
52. Leleu X., Fouquet G., Hebraud B., et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 2013, 27(11):2242-2244.
53. Mellqvist U.H., Gimsing P., Hjertner O., et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013, 121(23):4647-4654.
54. McCarthy P.L. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. JNatl Compr Canc Netw 2013, 11(1):35-42.
55. Ludwig H., Durie B.G., McCarthy P., et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012, 119(13):3003-3015.
56. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366(19):1770-1781.
57. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEngl J Med 2012, 366(19):1782-1791.
58. Shimizu K. Overview of the international myeloma workshop 2013 kyoto. Clin Lymphoma Myeloma Leuk 2014, 14(1):2-4.
59. Lauwers-Cances V., Marit G., Caillot D., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial. Blood 2013, 122(21):406.
60. Cavallo F., Caravita T., Cavalli M., et al. Maintenance therapy with lenalidomide significantly improved survival of yong newly diagnosed multiple myeloma patients. Blood 2013, 122(21):2089.
61. Palumbo A., Hajek R., Delforge M., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. NEngl J Med 2012, 366(19):1759-1769.
62. Scheid C., van der Holt B., el Jarari L., et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:extended follow-up of the HOVON-65/GMMG-HD4 trial. Blood 2013, 122(21):404.
63. Gahrton G., Iacobelli S., Björkstrand B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121(25):5055-5063.
64. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12(13):1195-1203.
65. Lokhorst H.M., van der Holt B., Cornelissen J.J., et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012, 119(26):6219-6225. [quiz: 6399].
66. Bruno B., Rotta M., Patriarca F., et al. Acomparison of allografting with autografting for newly diagnosed myeloma. NEngl J Med 2007, 356(11):1110-1120.
67. Kumar S., Zhang M.J., Li P., et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011, 118(7):1979-1988.
68. Keats J.J., Chesi M., Egan J.B., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120(5):1067-1076.
69. Bergsagel P.L., Mateos M.V., Gutierrez N.C., et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013, 121(6):884-892.
70. Palumbo A., Anderson K. Multiple myeloma. NEngl J Med 2011, 364(11):1046-1060.